For heavy periods, a hormonal IUD beat the usual pills in a large trial

Heavy menstrual bleeding is one of the most common reasons women see a doctor, and the treatments on offer range from simple tablets to a hormone-releasing coil to surgery. A large trial run in ordinary general practice — the setting where most women first raise the problem — found that the hormonal intrauterine device outperformed the usual first-line pills on the measure that matters most: how much the bleeding disrupts daily life [s1].

What the trial compared

The ECLIPSE trial randomly assigned 571 women with menorrhagia who presented to their primary care providers to one of two approaches: the levonorgestrel-releasing intrauterine system (the hormonal coil) or usual medical treatment [s1]. Usual treatment was not a single drug but whatever the clinician judged best — tranexamic acid, mefenamic acid, a combined estrogen-progestogen pill, or progesterone alone [s1].

Rather than measure millilitres of blood, the trial used a patient-reported score, the Menorrhagia Multi-Attribute Scale, which runs from 0 to 100 with lower scores meaning more severe impact on life [s1]. It tracked that score over two years, capturing not just whether bleeding eased but whether women's work, social life and wellbeing improved [s1].

What it found

Both groups got better. Scores improved from baseline to six months in each, with a mean increase of 32.7 points in the coil group and 21.4 points in the usual-treatment group (P<0.001 for both) [s1]. The gains held over the full two years, but they were consistently larger with the coil: the mean between-group difference was 13.4 points (95% confidence interval 9.9 to 16.9, P<0.001) [s1]. The coil came out ahead on every domain of the score — practical difficulties, social life, family life, work and daily routine, psychological wellbeing and physical health — and on seven of the eight general quality-of-life domains [s1].

A second signal came from what women chose to keep doing. At two years, 64% of the coil group were still using their assigned treatment, against 38% of the usual-treatment group (P<0.001) [s1] — a large gap, since a treatment only helps if people stay on it. There were no significant differences between the groups in rates of surgery, in sexual-activity scores, or in serious adverse events [s1].

The wider evidence agrees

ECLIPSE is not a lone result. A Cochrane systematic review of progestogen-releasing intrauterine systems for heavy menstrual bleeding concluded that the device may improve bleeding and quality of life compared with other medical therapy [s2]. Against more invasive options the picture is more nuanced: the review judged the coil probably similar to endometrial destruction techniques, and was uncertain whether it is better or worse than hysterectomy [s2]. On safety, it found the coil probably has similar serious adverse events to other medical therapy [s2].

That combination — a pragmatic trial in real general practice plus a systematic review pooling many studies — is about as solid as evidence in this area gets, and both point the same way for a first treatment choice.

How to read it

The comparison ECLIPSE actually tested was the hormonal coil against first-line tablets, not against surgery, so it supports the coil as an early option, not as a replacement for procedures some women will still need [s1]. The trial measured impact on life rather than exact blood loss, which is a strength for a symptom defined largely by how much it bothers a woman, but it means the numbers are about wellbeing, not millilitres [s1]. And the coil is not right for everyone: it must be fitted, can cause irregular spotting in the first months, and suits some women's circumstances better than others.

Heavy bleeding also has causes that need their own assessment — fibroids, adenomyosis, polyps, clotting disorders, and, rarely, cancer of the womb lining. Bleeding that is new after menopause, or that comes with severe pain or symptoms of anaemia such as breathlessness and marked fatigue, warrants medical review rather than self-management.

The liftable summary: for heavy periods first raised with a GP, the levonorgestrel coil improved quality of life more than standard tablets over two years and more women stuck with it — and a Cochrane review backs it as an effective option. It is a strong first choice, not the only one.

This article is informational and is not medical advice. Treatment for heavy menstrual bleeding should be decided with a clinician.